Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval By Brian Park, PharmD Publish Date August 16, 2019
Terlipressin Reverses Hepatorenal Syndrome Type 1 in Phase 3 Trial By Steve Duffy Publish Date August 16, 2019
Nomacopan Gets Fast-Tracked for Post-Transplant Thrombotic Microangiopathy By Steve Duffy Publish Date August 15, 2019
Evinacumab Effective in Homozygous Familial Hypercholesterolemia Trial By Diana Ernst, RPh Publish Date August 14, 2019
Istaroxime Fast-Tracked for Acute Heart Failure Treatment By Brian Park, PharmD Publish Date August 14, 2019
Cardiorenal Effects of Sotagliflozin Evaluated in T1D Patients By Brian Park, PharmD Publish Date August 12, 2019
Investigational Antisense Medicine Gets Orphan Drug Status for Centronuclear Myopathies By Brian Park, PharmD Publish Date August 9, 2019
FDA to Review Lotion Formulation of Tazarotene for Acne Treatment By Steve Duffy Publish Date August 7, 2019
Therapy That Targets Underlying Cause of Dravet Syndrome Gets Orphan Drug Status By Brian Park, PharmD Publish Date August 7, 2019
Givosiran NDA for Acute Hepatic Porphyria Granted Priority Review By Brian Park, PharmD Publish Date August 6, 2019
Teplizumab Gets Breakthrough Status for Type 1 Diabetes Prevention By Steve Duffy Publish Date August 6, 2019
NDA for Investigational Rosacea Treatment Submitted to FDA By Steve Duffy Publish Date August 5, 2019
Elagolix NDA Submitted for Heavy Menstrual Bleeding With Uterine Fibroids By Diana Ernst, RPh Publish Date August 5, 2019
Bempegaldesleukin Combo Regimen Gets Breakthrough Status for Untreated Advanced Melanoma By Brian Park, PharmD Publish Date August 1, 2019
Triheptanoin NDA Submitted for Long-Chain Fatty Acid Oxidation Disorders By Diana Ernst, RPh Publish Date August 1, 2019
Diroximel Fumarate Goes Head-to-Head With Dimethyl Fumarate in GI Tolerability Study By Diana Ernst, RPh Publish Date July 30, 2019
Nipocalimab Gets Fast-Tracked for Hemolytic Disease of the Fetus and Newborn By Brian Park, PharmD Publish Date July 30, 2019
